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A B S T R A C T
Purpose: The purpose of this study was to identify the prevalence of mutations in the Myoclonin1/EFHC1
gene in Mexican patients with juvenile myoclonic epilepsy (JME).
Method: We studied forty-one patients at the National Institute of Neurology and Neurosurgery in
Mexico City and 100 healthy controls. DNA was extracted from the peripheral venous blood of all
participants. The exons of EFHC1 were then ampliﬁed and sequenced.
Results: We found three new putative mutations, all of which were heterozygous missense mutations
located in exon 3. The ﬁrst identiﬁed mutation, 352C>T, produces a R118C change in the protein and
cosegregated in the patient’s affected father and brother. The second identiﬁed mutation, 544C>T,
produces a R182L change in the protein and was found in the patient’s asymptomatic father. The third
identiﬁed mutation, 458>A, produces a R153Q change in the protein and was also found in the patient’s
father. These mutations were not found in controls.
Conclusions: The frequency of Myoclonin1/EFHC1 mutations in our sample is 7.3%. Thus, we conclude that
mutations in the Myoclonin1/EFHC1 gene are an important cause of JME in Mexican patients.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) is one of the most common
types of genetic generalized epilepsy.1 JME is characterized by
adolescent onset, infrequent absence seizures, awakening myoclon-
ic seizures and generalized tonic–clonic (GTC) or clonic–tonic–
clonic (CTC) seizures. Two JME-causing genes have been identiﬁed
and their associations with JME have been replicated. These genes
include GABRA1 on chromosome 5q34q352,3 and EFHC1 on
chromosome 6p12.4 In another study, 9% of JME patients from* Corresponding author at: Insurgentes Sur #3877, Col. La Fama, Del. Tlalpan,
Mexico City 14269, Mexico. Tel.: +52 55 56063822x2022; fax: +52 55 54240808.
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http://dx.doi.org/10.1016/j.seizure.2012.05.016Honduras and Mexico and 3% of JME patients from Japan were found
to carry heterozygous missense, nonsense and deletion frameshift
mutations in the EFHC1 gene.5 Here, we report the presence of three
additional novel EFHC1 heterozygous missense mutations in a new
cohort of forty-one Mexican JME patients. We also compared the
presence of the JME subsyndromes and the persistence of seizures in
JME patients with and without EFHC1 mutations.
2. Methods
2.1. Patient and family samples
Forty-one Mexican JME patients were recruited for the present
study from the National Institute of Neurology and Neurosurgery
(NINN) in Mexico City. The diagnosis of JME was established by two
epileptologists using the following inclusion criteria. (a) The onset
of myoclonic seizures presented between 8 and 20 years of age. The
myoclonic seizures experienced by the patient were characterizedvier Ltd. All rights reserved.
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tions. These seizures predominantly manifested in the shoulders
and arms and were less frequently observed in the legs. There was no
evidence of loss of consciousness with the seizures. (b) Interictal EEG
of the patient showed diffuse, bilateral, symmetrical and synchro-
nous 3–6 Hz spike, polyspike and slow wave complexes. (c) The
presence of GTC or CTC seizures at the onset or over the course of the
disease. (d) The patient was required to have a normal neurological
exam. (e) The patient was required to have normal brain
neuroimaging studies, such as computed tomography and/or
magnetic resonance imaging, at the onset of symptoms.
The exclusion criteria for patients in the study included: (a)
history of symptomatic seizures; (b) family history of progressive
myoclonic epilepsy; (c) evidence of a progressive neurological
disease that could cause epilepsy and (d) presence of simple partial
or complex seizures.5 When EFHC1 mutations were identiﬁed in
the patients, blood was drawn from the proband’s family members
for DNA analysis. The family members also underwent EEG.
Informed consent was obtained from all participants, and the study
was approved by the Bioethics Committee of the NINN. We also
obtained the donated blood samples of 100 anonymous individuals
without a history of seizures from the NINN blood bank. These
samples were tested as ethnically matched healthy controls. Next,
we categorized each of the forty-one JME patients into one of the
four previously described JME subsyndromes.1 Comparisons of theFig. 1. Families with novel EFHC1 mutations. Brief description: Circles: female; Square:
affected subjects; M: mutated; N: no mutated. *Normal EEG. **Abnormal EEG.JME phenotypes and the persistence of seizures between patients
with and without EFHC1 mutations were made using x2 or Fisher’s
exact test. The data were analyzed using SPSS version 17.
2.2. DNA sequencing
Peripheral venous blood was drawn from forty-one JME patients
and 100 healthy controls. Blood was also drawn from seven family
members of the probands with EFHC1 mutations. DNA was extracted
from each blood sample using the QIAmp DNA blood Mini Kit
(QIAGEN, Valencia, CA, USA). The exons of EFHC1 were ampliﬁed
using the primers and polymerase chain reaction (PCR) conditions
described by Suzuki et al.4 The PCR products were then puriﬁed and
sequenced using the Big Dye Terminator sequencing reactions in an
automated DNA sequencer (ABI PRISM 3130 Applied Biosystems,
Foster City, CA). The identiﬁed variants were sequenced at least
twice in both the forward and reverse directions.
3. Results
3.1. Clinical characteristics
In our cohort of 41 JME patients, 25 (61%) were female. The average
age at onset of epilepsy was 14.24 years (range 5–20 years). Twenty-
one subjects (51.2%) had a positive family history of epilepsy. The male; Circles and square ﬁlled: affected subjects; Circles and square empty: non
Fig. 2.
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four patients (10%) had CAE that evolved into JME, two patients (5%)
met the criteria for JME with adolescent-onset pyknoleptic and two
patients (5%) met the criteria for JME with astatic seizures.
3.2. Mutation analysis
The three new mutations (7.3%) identiﬁed in this cohort of JME
patients were heterozygous missense mutations. They have not
been previously reported in the single nucleotide polymorphism
database (SNPs). All three of the novel mutations are located in
exon 3 of the EFHC1 gene. The ﬁrst identiﬁed mutation, 352C>T,
changes the Myoclonin1 protein by substituting cysteine for
arginine at amino acid position 118 (R118C). This mutation was1                                                3
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Fig. 3. Diagram of genomic organization of the EFHCalso found in the patient’s affected father and brother (Fig. 1A). The
second mutation, 544C>T, substitutes lysine for arginine at
position 182 of the protein (R182L). The patient’s asymptomatic
father, who had a normal EEG, also carried the same mutation
(Fig. 1B). The third mutation, 458G>A, replaces an arginine with
glutamine at position 153 of the protein (R153Q). The patient’s
asymptomatic father also carried this mutation (Fig. 1C). None of
these mutations were found in the controls.
The three identiﬁed missense mutations, R118C, R153Q and
R182C, are found in exon 3. In silico analysis shows that the affected
region includes part of the ﬁrst DM10 domain (position 93–198)
(Figs. 2 and 3) and resides in an evolutionary conserved amino acid
sequence (EMBL Clustal W2). These mutations were predicted to
have damaging effects on function by the Polyphen program. The00                                                    640
1 DM1 EF
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1 gene. New mutations are shown in bold type.
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respectively.
The following previously described polymorphisms were also
identiﬁed: G545A was found in three patients; G475T was found in
four patients; G881A was found in one patient; and F1058C and
A1855C were found in two patients. None of these polymorphisms
appear to predispose individuals to JME.4
4. Discussion
In total, 674 SNPs variants have been identiﬁed in the EFHC1 gene.
They can be found in the human genome database (GENOME 1000).
Of these variants, 132 are located in exon regions. Prior to our
present report, 22 of these exon variants (18 missense variants, one
nonsense variant, one three-base deletion variant in the promoter
region, one variant in the 30UTR and one deletion/frameshift variant)
were considered to be heterozygous pathogenic mutations that
were transmitted as autosomal dominant traits. This assumption
was based on several pieces of evidence. (1) Some studies have
reported the segregation of EFHC1 mutations with the incidence of
epilepsy and EEG polyspike waves. These studies were based on
analyses of affected family members across 2–4 generations of 13
JME families from Mexico, Honduras, Japan and Italy. These ﬁndings
suggest that EFHC1 is a Mendelian gene that strongly predisposes
individuals to epilepsy in these rare families.4–6 (2) Additionally,
EFHC1 mutations were found to be transmitted by unaffected
parents to 12 JME singletons in studies conducted in Mexico, Austria,
Honduras, Tennessee (USA) and Japan. These ﬁndings support the
view that these mutations constitute an autosomal dominant trait
with incomplete penetrance.4–8 (3) Furthermore, the presence of
myoclonic and GTC seizures in efhc1/ mice has been reported and
replicated. This result proves that the loss of EFHC1 function alone is
sufﬁcient to cause epilepsy.9
Furthermore, the speciﬁc EFHC1 missense mutations of EFHC1
that segregate in families and are found in singletons may
potentially be pathogenic. The changes of the domain sites at
which EFHC1 mutations occur have potential deleterious func-
tional effects on the encoded myoclonin1 protein, as predicted by
‘‘in silico analysis’’. Further, the identiﬁed EFHC1 mutations are
often located in evolutionarily conserved domains. Finally,
functional studies of the effect of the individual missense
mutations in vitro indicate that the mutations are pathogenic.
For instance, the overexpression of EFHC1 in mouse hippocampal
primary neuronal cultures induced apoptosis. This apoptosis was
signiﬁcantly decreased in ﬁve types of hippocampal cells each with
a distinct EFHC1 missense mutation. These missense mutations
were double heterozygous 229C>A and 662>A; 685T>C; 628G>A;
757G>T; and 545G>A.4 In addition, patch clamp analysis of HEK
cell cultures revealed that EFHC1 speciﬁcally increased R-type Ca2+
currents. These currents were also shown to increase apoptotic
processes. The increased R-type Ca2+ currents were partially
reversed by each of ﬁve tested EFHC1 missense mutations.4
Analyses of the contribution of the EFHC1 variants to ‘‘epilepsy
risk’’ have also been performed. Bai et al.10 asked if the coding SNPs
of EFHC1 contributed to the development of epilepsy as minor
susceptibility alleles with small genetic displacements. This study
tested an oligogenic or polygenic hypothesis of epilepsy suscepti-
bility. Their study included 130 unrelated JME patients and 352
family members. No statistically signiﬁcant differences between
the JME probands and controls were found in the association
analysis. No transmission disequilibrium was found for the four
tested SNPs (rs3804506, rs3804505, rs1266787, rs17851770) in
the family-based association analysis.10 Thus, in this small cohort,
these four EFHC1 SNPs did not confer susceptibility for JME. To
date, the cosegregation of Myoclonin1/EFHC1 mutations with JME
has been reported in 13 JME families. We have identiﬁed anadditional Mexican family in which the R118C mutation segregat-
ed with the three affected members in two different generations.
The two other mutations that we have identiﬁed, R182L and
R152Q, were transmitted by unaffected parents to 2 unrelated
singletons. These mutations can be added to the 12 currently
known singleton EFHC1 mutations in the literature. The heterozy-
gous missense mutations reported here should be considered
putative mutations because functional studies of the effects of
these speciﬁc mutations have not yet been performed. We
originally screened 41 new JME patients to conﬁrm the frequency
of Myoclonin1/EFHC1 mutations in Mexican families. We wished
to perform this analysis in our own genetics laboratory, indepen-
dent of the Los Angeles epilepsy genomics/genetics laboratories.
It is too early to tell how many of the remaining 119 EFHC1
exonic variants reported in GENOME 1000 are pathogenic and how
frequently these mutations occur in various populations. However,
as described previously and in this report, EFHC1 mutations were
present in 7% to 9% of JME patients that presented to the
Neurology/Epilepsy Clinics of Mexico, Los Angeles and Hon-
duras.4,5 To date, the GENESS consortium has described fourteen
different EFHC1 mutations in unrelated JME families, including the
three mutations described in this paper. Most of these mutations
were also found in our Mexican sample. This result suggests that
EFHC1 mutations are frequently present in Mexican patients with
JME.4,5 In addition to the mutations found in the Mexican JME
families, heterozygous missense EFHC1 mutations have also been
described in Caucasian JME families from Italy,6 Austria,7 and
Tennessee, USA.8 Interestingly, EFHC1 mutations have been
identiﬁed in individuals with different idiopathic epilepsies and
one type of temporal lobe epilepsy. These results suggest that the
EFHC1 mutations may be pleiotropic and may be expressed as
various epilepsy phenotypes.7 Currently, EFHC1 mutations have
been primarily identiﬁed in JME probands. They are rarely found in
probands with juvenile absence and pure grand mal seizures.
However, EFHC1 mutations are found in the affected family
members of individuals with JME, pure grand mal seizures,
childhood pyknoleptic absence seizures, juvenile absence seizures
and adolescent astatic seizures.4–7 The identiﬁed EFHC1 mutations
include deletions, insertions and frameshifts that give rise to stop
codons. However, genes that encode loss of function proteins are
present in normal healthy individuals. Approximately 100 genuine
loss of function variants and 20 completely inactivated genes have
been estimated to exist in the human genome.11 Thus, the
identiﬁed mutations must undergo functional analysis before they
can be considered to cause epilepsy. This requirement is true for
the missense and stop codon mutations alike. Furthermore, the
presence of incomplete penetrance may explain the reason that the
patients’ fathers in families B and C remain asymptomatic and have
normal EEGs despite carrying EFHC1 mutations.4
Several lines of evidence point to the mechanisms through
which the impaired functions or loss of function mutations of
EFHC1 may cause epilepsy. In vitro studies of mitosis in various cell
lines as well as in vivo studies in Drosophila melanogaster, show that
EFHC1 is a microtubule-associated protein. EFHC1 co-localizes with
the mitotic spindle, especially with the spindle poles and
midbody.12 In the in vitro experiments, the loss of EFHC1 function
disrupts mitotic spindle organization, impairs M phase progres-
sion, prevents microtubule bundling and increases apoptosis.12
Experiments in the developing rat cortex have shown that the
knockdown of EFHC1 by ex vivo and in utero electroporation with
iRNA disrupts projection neuroblast radial migration. Several steps
of neurogenesis are affected to achieve this effect. The cell division,
mitosis and cell cycle exit of cortical progenitors are disrupted.
Additionally, the organization of the radial glia scaffold and the
locomotion of postmitotic neurons in the intermediate zone are
disturbed. The abnormalities in all of these steps contribute to the
A. Jara-Prado et al. / Seizure 21 (2012) 550–554554neuronal migration defects.13 In vivo studies of Drosophila
melanogaster knocked out for the Defhc1.1 gene, a homolog of
EFHC1, have also been performed. The KO mutants exhibit
increased synaptic bouton proliferation, overgrowth of dendritic
arbors and augmented neurotransmitter release. Transfection of
the mutant with Defhc1.1 rescues synaptic bouton proliferation,
decreases dendritic elaboration and augments neurotransmitter
release.14 Based on these in vitro and in vivo functional studies, loss
of function mutations in the Myoclonin1/EFHC1 gene may induce
epileptogenesis by disturbing microtubule cytoskeleton dynamics,
increasing microtubule bundling, increasing synaptic bouton
proliferation and dendritic arborization and augmenting neuro-
transmitter release. The disturbance of these processes may
ultimately cause seizures. Because Myoclonin1/EFHC1 also reg-
ulates neuronal migration during cortical development, the
disruption of projection neuroblast migration may also result in
cortical and subcortical microdysgenesis and lead to the establish-
ment of anatomical epileptogenic networks.12–14
5. Conclusions
We report that the R118C heterozygous mutation in the EFHC1
gene cosegregates with three affected members across two
generations in one family. Our study also observed two other
novel mutations, R182L and R152Q. These mutations were
transmitted by asymptomatic fathers to unrelated singletons.
This result suggests that these autosomal dominant EFHC1
mutations exhibit incomplete penetrance. Until functional studies
show the deleterious effects of these mutations on the Myoclonin1
protein, however, they remain putative risk alleles for epilepsy.
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